Pine Bark Extract (Pycnogenol) for Asthma Support

Research suggests that Pycnogenol, a standardized extract derived from French maritime pine bark, may offer adjunctive benefits for asthma management, with several randomized controlled trials reporting improvements in lung function, symptom control, rescue inhaler use, and inflammatory markers such as urinary leukotrienes, as well as one trial finding that a majority of participants taking Pycnogenol alongside standard inhaled corticosteroid therapy were able to reduce their corticosteroid dose compared to very few in the control group. Studies indicate that these effects may be tied to Pycnogenol's ability to inhibit inflammatory pathways, including 5-lipoxygenase and COX-2, which are directly relevant to asthma pathophysiology. However, multiple systematic reviews and meta-analyses — including a Cochrane-style review pooling data from 27 trials — consistently rate the overall quality of evidence as very low, citing small sample sizes, inconsistent outcome measures, and limited numbers of trials per condition, and they stop short of drawing firm conclusions about whether Pycnogenol is genuinely effective or safe for asthma. The existing body of research points toward a plausible and potentially promising direction, but reviewers broadly agree that larger, more rigorously designed trials are needed before any definitive assessment can be made.